Genzyme CEO on Board With Savient
Savient Pharmaceuticals elected David Meeker, M.D., President and Chief Executive Officer at Genzyme, a Sanofi Company, to its Board of Directors. Dr. Meeker has an extensive amount of expertise in the life science industries and is adept at leading companies to their highest achievements. Prior to his role as President and Chief Executive Officer at Genzyme, Dr. Meeker was Genzyme’s President of Global Rare Disease Business. In this role, he oversaw the global launches of Aldurazyme, Fabrazyme, and Myozyme. Before coming to Genzyme, Dr. Meeker was the Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic. He is also a Board member at the Biotechnology Industry Organization and Prize4life. He received an MD from the University of Vermont Medical School and completed the Advanced Management Program at Harvard Business School.
AstraZeneca Expands Executive Leadership Team
AstraZeneca recently named 12 members to its expanded executive leadership team. They are: Pascal Soroit, Chief Executive Officer and Executive Director; Simon Lowth, Chief Financial Officer and Executive Director; Mene Pangalos, Executive Vice President, Innovative Medicines; Bahija Jalla, Executive Vice President, Medlmmune; Briggs Morrison, Executive Vice President, Global Medicines Development; Paul Hudson, Executive Vice President, North America; Ruud Dobber, Executive Vice President, Europe; Mark Mallon, Executive Vice President, International; David Smith, Executive Vice President, Operations & IS; Lynn Tetrault, Executive Vice President, Human Resources & Corporate Affairs; Katarina Ageborg, Chief Compliance Officer; and Jeff Pott, General Counsel. The team will contribute to the company’s scientific expertise, key products, and key markets. The new changes include three research and development roles for discovery and early stage development in small molecules; three roles representing regions of North America, Europe and International; and global portfolio and product strategy.
This Could Be You!
The 2012 Trailblazer Brand Champion of the Year for Diabetes/Metabolic Disorders is Melissa Bojorquez of Boehringer Ingelheim. She and 41 other brand champions are now members of the PM360 Hall of Fame. Do you belong there? Do you know someone who does? Go to PM360TrailblazerAwards.com today, download the guidelines, and send your entries in!
Atherotech Diagnostics Lab
Michael Tarwater joined Atherotech Diagnostics Lab as Vice President of Information Technology. He will oversee the IT department and develop new strategic IT plans that can be added to the company’s vision, mission, and growth. Tarwater’s proven track record with Fortune 500 clients includes work in manufacturing, distribution, eCommerce and the retail sectors.
Mike Burgess M.D., Ph.D., joined Bristol-Myers Squibb as Senior Vice President, Discovery Medicine and Clinical Pharmacology. The University of Bristol graduate adds his expertise to the research and development department. Previously, Burgess served as Interim Head of Hoffman La-Roche’s Pharma Research and Early Development Organization, and served Eli Lilly and Company as a Medical Fellow.
The biotechnology company elected John G. Cooper, CPA, as Board Director, and appointed him President and Chief Executive Officer. He comes into his new role after serving eight years as Executive Vice President and Chief Financial Officer at Discovery Labs. Cooper will also retain his current position as CFO.
The leading developer of small molecules for the treatment of cardiometabolic disorders appointed Tim Mayleben President and CEO. In his new role, Mayleben’s set to lead Esperion’s successful product, ETC-1002, a small molecule used to treat patients with hypercholesterolemia, to its fullest potential.
With 20 years experience in marketing access, Barbara Jaszewski has been named Vice President of Global Pricing and Market Access. In her new role, she will be responsible for the introduction of three new drugs: vortioxetine, nalmefene, and andaripiprazole. Jaszewski previously served as Director of Global Market Access, Bayer Healthcare, where she was accountable for the company’s worldwide marketing activities.
Novo Nordisk, Inc.
The global healthcare company headquartered in Denmark announces the promotion of Curtis G. Oltmans as Corporate Vice President and General Counsel for legal and quality affairs, and joins the company’s U.S. executive team. In June 2005, Oltmans started at Novo Nordisk as Vice President and Deputy General Counsel overseeing the legal team. In the North America office, he is responsible for preparing initiatives for the following areas: law, quality, intellectual property, grants and philanthropy.
Roche hired one of the top biomedical researchers, John C. Reed, M.D., Ph.D., as Head of Roche Pharma Research and Early Development and as a member of the enlarged Corporate Executive Committee. Prior to Roche, Reed held the CEO position at Sanford-Burnham Medical Research Institute.
The global and diversified healthcare leader appoints Gary J. Nabel, M.D., Ph.D., as Chairman of the Strategic Development and Scientific Advisory Council. A Harvard graduate, Nabel is currently the Senior Vice President, Chief Scientific Officer at Global R&D. As council, he is responsible for managing selection, appointment and evaluation of advisors.
The privately held biopharmaceutical company hired 2011 Nobel Prize recipient in Physiology or Medicine, Bruce A. Beutler as a Scientific Advisor. Sound Pharmaceutical was the first company to develop drugs for hearing loss, an area in which Beutler has an extensive amount of knowledge. Beutler was responsible for identifying COMTz, a genetic mutation that leads to human deafness. He currently serves as Director of the Center for the Genetics of Host Defense at the University of Texas Southwestern Medical Center.
Symphony Health Solutions
Appointed the company’s new Chief Executive Officer, Frank Lavelle who will drive customer-centric innovation for information and analytics. Previously, Lavelle served as CEO for Siemens Medical Solutions, President for Medquist, and President and CEO for SunGard Data Systems’ K12 Divison.
The multinational specialty pharmaceutical company announced Laizer D. Kornwasser as Executive Vice President/Company Group Chairman. As Executive VP, he will direct operations in Canada, U.S. Neurology and other functions throughout the U.S. Prior to his appointment at Valeant, he served as Senior Vice President, Consumer Solutions and Retail Markets at Medco Health.